Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Gains from Sales and Divestitures: 2020-2024

Historic Gains from Sales and Divestitures for Tango Therapeutics (TNGX) over the last 4 years, with Dec 2024 value amounting to $260,865.

  • Tango Therapeutics' Gains from Sales and Divestitures rose 79.53% to $454,414 in Q3 2025 from the same period last year, while for Sep 2025 it was $454,414, marking a year-over-year increase of 79.53%. This contributed to the annual value of $260,865 for FY2024, which is 595.64% up from last year.
  • According to the latest figures from FY2024, Tango Therapeutics' Gains from Sales and Divestitures is $260,865, which was up 595.64% from $37,500 recorded in FY2023.
  • In the past 5 years, Tango Therapeutics' Gains from Sales and Divestitures ranged from a high of $788,227 in FY2020 and a low of $37,500 during FY2023.
  • Its 2-year average for Gains from Sales and Divestitures is $149,182, with a median of $149,182 in 2023.
  • As far as peak fluctuations go, Tango Therapeutics' Gains from Sales and Divestitures slumped by 67.45% in 2021, and later spiked by 595.64% in 2024.
  • Tango Therapeutics' Gains from Sales and Divestitures (Yearly) stood at $788,227 in 2020, then crashed by 67.45% to $256,598 in 2021, then reached $37,500 in 2023, then soared by 595.64% to $260,865 in 2024.